Efficacy of Acupuncture on Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Clinical Trial

Official title: Efficacy of Acupuncture on Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Phase III, Randomized, Sham-controlled Clinical Trial

Status Recruiting

Clinical Trial Summary

The purpose of this study is to assess the neurological efficacy of acupuncture in patients with cancer who experienced peripheral neuropathy, which is induced by chemotherapy.

Clinical Trial Description

Background: Chemotherapy may lead to peripheral neuropathy up to 40% in cancer survivors, especially in some types of patients with cancer. The effect of acupuncture, an ancient Chinese medicine technique, was recognized by the World Health Organization (WHO) in the treatment of several diseases. The postulated mechanisms associated with acupuncture in analgesia or neurogenesis are still under investigation. Considering a moderate recommendation for duloxetine in the treatment of chemotherapy-induced peripheral neuropathy (CIPN) based on based on neuropathic pain, and a few treatment options with evidence for CIPN, acupuncture might be another option. Nowadays, only small scale pilot studies provided initial proof of acupuncture in CIPN, particularly in decreasing neuropathic pain and improving neurotoxicity, the study aims to determine the beneficial effects of acupuncture on CIPN with a large-scale, multicenter, randomized sham-controlled clinical trial. Furthermore, the aim of the study will provide evidence for the clinical therapeutic guideline of CIPN in the future. ;

Related Conditions & MeSH terms

• Chemotherapy-Induced Peripheral Neuropathy (CIPN)
• Peripheral Nervous System Diseases

• NCT number: NCT04739631
• Study type: Interventional
• Source: Taipei Veterans General Hospital, Taiwan
• Contact: Fang-Pey Chen, Ph.D
• Phone: 886-2-28757453
• Email: fpchen@vghtpe.gov.tw
• Status: Recruiting
• Phase: N/A
• Start date: January 22, 2021
• Completion date: June 30, 2022